RU2390524C2 - Способ концентрирования препаратов антител - Google Patents

Способ концентрирования препаратов антител Download PDF

Info

Publication number
RU2390524C2
RU2390524C2 RU2007110534/13A RU2007110534A RU2390524C2 RU 2390524 C2 RU2390524 C2 RU 2390524C2 RU 2007110534/13 A RU2007110534/13 A RU 2007110534/13A RU 2007110534 A RU2007110534 A RU 2007110534A RU 2390524 C2 RU2390524 C2 RU 2390524C2
Authority
RU
Russia
Prior art keywords
ultrafiltration
antibody preparation
antibody
diafiltration
concentration
Prior art date
Application number
RU2007110534/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2007110534A (ru
Inventor
Чарльз Мэттью УИНТЕР (US)
Чарльз Мэттью УИНТЕР
Original Assignee
Джэнентек, Инк.
Новартис, Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2390524(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джэнентек, Инк., Новартис, Аг filed Critical Джэнентек, Инк.
Publication of RU2007110534A publication Critical patent/RU2007110534A/ru
Application granted granted Critical
Publication of RU2390524C2 publication Critical patent/RU2390524C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)
RU2007110534/13A 2004-09-09 2005-09-08 Способ концентрирования препаратов антител RU2390524C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US60/609,092 2004-09-09
US11/220,362 2005-09-06
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof

Publications (2)

Publication Number Publication Date
RU2007110534A RU2007110534A (ru) 2008-10-20
RU2390524C2 true RU2390524C2 (ru) 2010-05-27

Family

ID=35996499

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007110534/13A RU2390524C2 (ru) 2004-09-09 2005-09-08 Способ концентрирования препаратов антител

Country Status (32)

Country Link
US (6) US20060051347A1 (enExample)
EP (5) EP1786830B1 (enExample)
JP (2) JP5210633B2 (enExample)
KR (2) KR101528970B1 (enExample)
CN (3) CN104961797B (enExample)
AR (1) AR050641A1 (enExample)
AU (1) AU2005285243C1 (enExample)
BR (1) BRPI0515649B8 (enExample)
CA (1) CA2577317C (enExample)
DK (5) DK4108259T3 (enExample)
EC (1) ECSP077282A (enExample)
ES (5) ES2528541T3 (enExample)
FI (4) FI4104859T3 (enExample)
GT (1) GT200500254A (enExample)
HU (4) HUE067662T2 (enExample)
IL (2) IL181372A (enExample)
LT (4) LT4104859T (enExample)
MA (1) MA28991B1 (enExample)
MX (2) MX2007002812A (enExample)
MY (2) MY162525A (enExample)
NO (1) NO333660B1 (enExample)
NZ (1) NZ553239A (enExample)
PE (1) PE20060816A1 (enExample)
PL (5) PL3805248T3 (enExample)
PT (5) PT4108259T (enExample)
RU (1) RU2390524C2 (enExample)
SG (1) SG177161A1 (enExample)
SI (5) SI4104859T1 (enExample)
TN (1) TNSN07069A1 (enExample)
TW (1) TWI372630B (enExample)
WO (1) WO2006031560A2 (enExample)
ZA (1) ZA200701626B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
EP2532742B1 (en) 2004-01-30 2018-08-08 Shire Pharmaceuticals Ireland Limited Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject
EP1765294B1 (en) 2004-05-12 2008-09-24 Baxter International Inc. Nucleic acid microspheres, production and delivery thereof
PT1758558E (pt) 2004-05-12 2013-12-05 Baxter Healthcare Sa Microesferas contendo oligonucleótidos, sua utilização para o fabrico de um medicamento para o tratamento de diabetes do tipo 1
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
EP2007506B1 (en) * 2006-03-31 2014-03-19 Danisco US Inc. Tangential flow filtration apparatuses, systems, and processes for the separation of compounds
NO347673B1 (no) 2006-04-04 2024-02-19 Takeda Pharmaceuticals Co En sammensetning som omfatter konsentrert polypeptide og bruk derav.
RU2476442C2 (ru) * 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
AU2008277886B8 (en) * 2007-07-17 2013-08-01 F. Hoffmann-La Roche Ag Variable tangential flow filtration
US20100249384A1 (en) * 2007-11-29 2010-09-30 Stefan Hepbildikler Immunoglobulin aggregates
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20150080038A (ko) * 2007-11-30 2015-07-08 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
CA2721037C (en) 2008-04-15 2018-05-22 Talecris Biotherapeutics, Inc. Methods for preparing a concentrated plasma product formulation using ultrafiltration/diafiltration
CN102124027B (zh) * 2008-05-15 2015-01-21 温氏健康有限公司 产生富含分泌型免疫球蛋白的乳组分的方法
CA2744510A1 (en) * 2008-12-09 2010-06-17 F.Hoffmann-La Roche Ag Method for obtaining an excipient-free antibody solution
EP2393579B1 (en) * 2009-01-21 2017-03-08 Smartflow Technologies, Inc. Optimization of separation for viscous suspensions
AU2010221156A1 (en) * 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
EP2411125B1 (en) * 2009-03-24 2019-05-08 Wyeth LLC Membrane evaporation for generating highly concentrated protein therapeutics
MX2011012576A (es) 2009-05-27 2012-05-08 Baxter Int Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo.
CA2772846C (en) * 2009-09-29 2020-09-29 F. Hoffmann-La Roche Ag Pre-filtration adjustment of buffer solutes
ES2604103T3 (es) * 2009-10-01 2017-03-03 F. Hoffmann-La Roche Ag Filtración final de una preparación de inmunoglobulina en múltiples pasos
EP2531218B1 (en) 2010-02-04 2018-12-12 CSL Behring AG Immunoglobulin preparation
EA201892184A1 (ru) 2010-03-01 2019-03-29 БАЙЕР ХЕЛЬСКЕР ЛЛСи Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
WO2013009686A2 (en) 2011-07-08 2013-01-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
SG11201400260TA (en) 2011-09-01 2014-03-28 Chugai Pharmaceutical Co Ltd Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2014102370A1 (en) * 2012-12-28 2014-07-03 Novo Nordisk A/S High temperature dead end antibody filtration
CN112126634A (zh) 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
EP3142775A2 (en) 2014-05-13 2017-03-22 Amgen Inc. Process control systems and methods for use with filters and filtration processes
WO2015195453A2 (en) 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
EP2957335B1 (en) * 2014-06-16 2020-05-27 EMD Millipore Corporation Single-pass filtration systems and processes
WO2015195452A2 (en) * 2014-06-16 2015-12-23 Emd Millipore Corporation Single-pass filtration systems and processes
EP4144434B1 (en) * 2014-06-16 2024-04-17 EMD Millipore Corporation Single-pass filtration systems and processes
CN106132517B (zh) 2014-06-25 2019-12-13 Emd 密理博公司 过滤器元件、切向流过滤系统、液体过滤工艺
SG10201901555UA (en) 2014-08-29 2019-03-28 Emd Millipore Corp Single Pass Tangential Flow Filtration Systems and Tangential Flow Filtration Systems withRecirculation of Retentate
SG10202006102UA (en) 2014-08-29 2020-07-29 Emd Millipore Corp Processes For Filtering Liquids Using Single Pass Tangential Flow Filtration Systems AndTangential Flow Filtration Systems With Recirculation of Retentate
EP3209332B1 (en) 2014-10-23 2021-05-26 Amgen Inc. Reducing viscosity of pharmaceutical formulations
CN106999588A (zh) 2014-12-03 2017-08-01 瑞士杰特贝林生物制品有限公司 具有增加的稳定性的包含免疫球蛋白的药物产品
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2017051273A1 (en) * 2015-09-22 2017-03-30 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
EP3468698B1 (en) 2016-06-09 2022-06-29 EMD Millipore Corporation Radial-path filter elements, systems and methods of using same
WO2018035116A1 (en) * 2016-08-16 2018-02-22 Genzyme Corporation Methods of processing a fluid including a recombinant therapeutic protein and use thereof
CN110198952B9 (zh) * 2016-08-17 2024-05-28 勃林格殷格翰国际公司 制备含有生物分子的高度浓缩的液体制剂的方法
US20180110856A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical Formulations and Methods of Making the Same
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
WO2019132418A1 (ko) * 2017-12-27 2019-07-04 ㈜셀트리온 투석 여과 방법
IL277797B1 (en) * 2018-04-12 2024-11-01 Amgen Inc Methods for making stable protein compositions
TWI898645B (zh) 2018-05-04 2025-09-21 美商健臻公司 灌注式細胞培養裝置
EP3833327A1 (en) * 2018-08-10 2021-06-16 Amgen Inc. Method of preparing an antibody pharmaceutical formulation
WO2020036903A1 (en) * 2018-08-14 2020-02-20 Bristol-Myers Squibb Company Improved protein recovery
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
NZ777640A (en) * 2019-02-15 2025-11-28 Merck Sharp & Dohme Automated biomanufacturing systems, facilities, and processes
BR112021024720B1 (pt) * 2019-07-31 2022-09-27 Catalent U.K. Swindon Zydis Limited Sistema e método para dosar uma formulação farmacêutica
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
JP2023544410A (ja) * 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
US20240001304A1 (en) 2020-11-23 2024-01-04 Abec, Inc. Filtration Systems, Components and Methods
WO2022191891A1 (en) * 2021-03-08 2022-09-15 Boehringer Ingelheim International Gmbh Systems and methods for single pass counter current diafiltration
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
IL314394A (en) 2022-02-25 2024-09-01 Amgen Inc Methods for preparing high-concentration liquid drug substances
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
CA3261698A1 (en) * 2022-07-12 2024-01-18 Beigene Switzerland Gmbh METHODS FOR PREPARING A HIGHLY CONCENTRATED PD1 ANTIBODY SOLUTION BY ULTRAFILTRATION/DIAFILTRATION (UF/DF)
CN115873064A (zh) * 2022-09-27 2023-03-31 英脉生物医药(杭州)有限公司 高浓度蛋白样品的制备装置及方法
AU2024260197A1 (en) * 2023-04-25 2025-11-13 Enzene Biosciences Limited In line cleaning in place process for alternating tangential flow filter
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies
CA3237624A1 (en) 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
US20040167320A1 (en) * 2003-02-24 2004-08-26 Couto Daniel E. Methods of tangential flow filtration and an apparatus therefore

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (enExample) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ZA847349B (en) 1983-10-05 1985-04-24 Solco Basel Ag Process for the preparation of a biologically active extract
US4786501A (en) * 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
GB2218703B (en) 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
AU4803890A (en) 1988-12-15 1990-07-10 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
SI1516628T1 (sl) 1995-07-27 2013-10-30 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
JP2001516599A (ja) * 1997-09-22 2001-10-02 セプラジェン コーポレーション ホエータンパク質の逐次分離およびその配合物
WO2000024266A2 (en) 1998-10-26 2000-05-04 Galagen, Inc. Soy and immunoglobulin compositions
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
AU5719600A (en) 1999-07-07 2001-01-30 New Zealand Co-Operative Dairy Company Limited Method of obtaining protein isolates and concentrates from colostrum
IL149008A0 (en) 1999-10-04 2002-11-10 Chiron Corp Stabilized liquid polypeptide-containing pharmaceutical compositions
DK1314437T3 (da) * 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
IL161812A0 (en) * 2001-11-13 2005-11-20 Genentech Inc Apo2 ligand/trail formulations
DK1478394T3 (da) 2002-02-27 2008-10-13 Immunex Corp Stabiliseret TNFR-Fc formulation med arginin
WO2004001007A2 (en) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
WO2004042012A2 (en) * 2002-11-01 2004-05-21 Bayer Healthcare Llc Process for concentration of macromolecules
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
KR20070009995A (ko) 2004-01-30 2007-01-19 수오멘 푸나이넨 리스티 베리팔베루 바이러스 안전성 면역글로불린을 제조하는 방법
WO2005082109A2 (en) 2004-02-26 2005-09-09 Massachusetts Institute Of Technology Solution additives for the attenuation of protein aggregation
WO2006018956A1 (ja) 2004-08-19 2006-02-23 Electronic Navigation Research Institute, An Independent Administrative Institution 誘電体レンズを用いた装置
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法
US11220362B2 (en) 2017-08-16 2022-01-11 O & M Halyard, Inc. Method and system for wrapping ties in a facemask manufacturing process

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
US20040167320A1 (en) * 2003-02-24 2004-08-26 Couto Daniel E. Methods of tangential flow filtration and an apparatus therefore

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WO/2004/042012, 21.05.2004. *

Also Published As

Publication number Publication date
EP3805248A2 (en) 2021-04-14
GT200500254A (es) 2006-08-02
DK3805248T5 (da) 2023-04-24
EP3805248A3 (en) 2021-07-14
BRPI0515649A (pt) 2008-07-29
BRPI0515649B1 (pt) 2021-10-13
HUE061899T2 (hu) 2023-08-28
FI4108259T3 (fi) 2024-09-10
KR20120135530A (ko) 2012-12-14
LT4104859T (lt) 2024-07-10
MX342788B (es) 2016-10-12
HK1101249A1 (en) 2007-10-12
JP2012097086A (ja) 2012-05-24
PL3805248T3 (pl) 2023-05-22
IL181372A0 (en) 2007-07-04
MX2007002812A (es) 2007-05-16
NO333660B1 (no) 2013-08-05
SG177161A1 (en) 2012-01-30
EP1786830A2 (en) 2007-05-23
PT3805248T (pt) 2023-04-05
FI2292636T3 (fi) 2024-01-12
SI4104859T1 (sl) 2024-08-30
US20070237762A1 (en) 2007-10-11
EP4108259A1 (en) 2022-12-28
BRPI0515649B8 (pt) 2021-11-03
EP4108259B1 (en) 2024-01-03
PL4108259T3 (pl) 2024-05-13
PL1786830T3 (pl) 2015-05-29
SI4108259T1 (sl) 2024-04-30
KR20070109975A (ko) 2007-11-15
HUE067662T2 (hu) 2024-11-28
US20060051347A1 (en) 2006-03-09
ES2968070T3 (es) 2024-05-07
DK4108259T3 (da) 2024-03-11
AU2005285243A1 (en) 2006-03-23
AR050641A1 (es) 2006-11-08
TWI372630B (en) 2012-09-21
PL2292636T3 (pl) 2024-03-11
CN102911268A (zh) 2013-02-06
PT4104859T (pt) 2024-07-02
DK2292636T3 (da) 2024-01-15
PT1786830E (pt) 2015-02-05
CA2577317C (en) 2016-04-26
DK4104859T3 (da) 2024-07-08
JP5210633B2 (ja) 2013-06-12
EP4104859B1 (en) 2024-04-17
EP2292636A2 (en) 2011-03-09
EP2292636A3 (en) 2013-05-01
LT3805248T (lt) 2023-04-25
US12371510B2 (en) 2025-07-29
EP3805248B1 (en) 2023-01-18
ZA200701626B (en) 2008-10-29
FI3805248T3 (fi) 2023-04-21
US20230074486A1 (en) 2023-03-09
SI3805248T1 (sl) 2023-05-31
HK1215869A1 (zh) 2016-09-23
PT2292636T (pt) 2024-01-09
US20210095050A1 (en) 2021-04-01
US20140370003A1 (en) 2014-12-18
JP5426641B2 (ja) 2014-02-26
EP4104859A1 (en) 2022-12-21
US11767370B2 (en) 2023-09-26
DK3805248T3 (da) 2023-04-03
NZ553239A (en) 2009-11-27
IL181372A (en) 2012-01-31
TW200612989A (en) 2006-05-01
NO20071432L (no) 2007-03-16
WO2006031560A2 (en) 2006-03-23
KR101528970B1 (ko) 2015-06-15
CN101056885B (zh) 2015-08-26
HUE067296T2 (hu) 2024-10-28
EP2292636B1 (en) 2023-10-18
PL4104859T3 (pl) 2024-08-26
SI1786830T1 (sl) 2015-03-31
JP2008512473A (ja) 2008-04-24
DK1786830T3 (en) 2015-01-19
AU2005285243B2 (en) 2012-03-08
WO2006031560A3 (en) 2006-08-24
US20090214522A1 (en) 2009-08-27
MY162525A (en) 2017-06-15
US10370456B2 (en) 2019-08-06
CN101056885A (zh) 2007-10-17
ES2975166T3 (es) 2024-07-03
EP1786830B1 (en) 2014-11-12
FI4104859T3 (fi) 2024-07-16
MA28991B1 (fr) 2007-11-01
CN104961797B (zh) 2020-12-25
LT4108259T (lt) 2024-04-10
CN104961797A (zh) 2015-10-07
ECSP077282A (es) 2007-03-29
IL216851A0 (en) 2012-01-31
ES2942574T3 (es) 2023-06-02
PE20060816A1 (es) 2006-09-02
MY150549A (en) 2014-01-30
KR101528970B9 (ko) 2022-12-09
SI2292636T1 (sl) 2024-02-29
HUE065025T2 (hu) 2024-04-28
ES2528541T3 (es) 2015-02-10
TNSN07069A1 (en) 2008-06-02
PT4108259T (pt) 2024-03-07
ES2983099T3 (es) 2024-10-22
EP2292636B9 (en) 2024-01-03
CA2577317A1 (en) 2006-03-23
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
AU2005285243C1 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
RU2390524C2 (ru) Способ концентрирования препаратов антител
JP2008512473A5 (enExample)
US6365395B1 (en) Process for removing protein aggregates and virus from a protein solution
RU2015103990A (ru) Способы культивирования клеток, размножения и очистки вирусов
RU2005129745A (ru) Способы и устройство проточной фильтрации вдоль потока
AR121861A2 (es) MÉTODO PARA PREPARAR UNA COMPOSICIÓN DE IgG ENRIQUECIDA A PARTIR DE PLASMA
JP6956824B2 (ja) 生体高分子ユニットおよびウイルスを液体から分離するための方法
JP2006515227A5 (enExample)
Higuchi et al. Surface modified polysulfone membranes: separation of mixed proteins and optical resolution of tryptophan
NO320952B1 (no) Fremgangsmate for virusfiltrering av en losning inneholdende minst ett makromolekyl
CA2584142A1 (en) Improved viral purification methods
JP2008514237A5 (enExample)
DK0923308T3 (da) Oprensning af biologisk aktive peptider fra mælk
ATE539149T1 (de) Reinigungsverfahren zur isolierung von gereinigtem vesikulärem stomatitisvirus aus zellkultur
CA2482512A1 (en) Improved viral purification methods
CN101076347A (zh) 用于集成连续生产生物分子的装置和方法
JPH06500730A (ja) 改良された接線フロー濾過法および装置
JP2015529447A5 (enExample)
JP2014210814A (ja) 中空糸膜を使用しての剪断感受性バイオポリマーを濃縮する方法
Castro-Muñoz et al. Current evidence in high throughput ultrafiltration toward the purification of monoclonal antibodies (mAbs) and biotechnological protein-type molecules
EP1037923B2 (fr) Procede de preparation par filtration d'une solution de facteur viii securisee viralement
EA201390154A1 (ru) Способ регенерации поливинилпирролидона из ретентата мембранного фильтра после осветления и стабилизации напитка, ферментированного дрожжами
Zhang et al. Selective separation of proteins by microfiltration with formed-in-place membranes
RU2009127772A (ru) Способ обработки потока веществ
WO2020004583A1 (ja) ポリペプチドの分離方法、ポリペプチドの製造方法及びポリペプチドの精製装置